Biomolecules · 2020 · 10 citations · 28 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsAnemiaHemoglobin PhysiologySickle Cell DiseaseAldehydesChemical Structure-activity RelationshipsCovalent InteractionsHemoglobin S PolymerizationHemoglobin-oxygen AffinityOxygen Affinity RegulationOxygen Binding AffinitySickle Cell Anemia
Aromatic aldehydes that bind to sickle hemoglobin (HbS) to increase the protein oxygen affinity and/or directly inhibit HbS polymer formation to prevent the pathological hypoxia-induced HbS polymerization and the subsequent erythrocyte sickling have for several years been studied for the treatment of sickle cell disease (SCD). With the exception of Voxelotor, which was recently approved by the U.S. Food and Drug Administration (FDA) to treat the disease, several other promising antisickling aromatic aldehydes have not fared well in the clinic because of metabolic instability of the aldehyde moiety, which is critical for the pharmacologic activity of these compounds. Over the years, our group has rationally developed analogs of aromatic aldehydes that incorporate a stable Michael addition reactive center that we hypothesized would form covalent interactions with Hb to increase the protein affinity for oxygen and prevent erythrocyte sickling. Although, these compounds have proven to be metabolically stable, unfortunately they showed weak to no antisickling activity. In this study, through additional targeted modifications of our lead Michael addition compounds, we have discovered other novel antisickling agents. These compounds, designated MMA, bind to the α-globin and/or β-globin to increase Hb affinity for oxygen and concomitantly inhibit erythrocyte sickling with significantly enhanced and sustained pharmacologic activities in vitro.
28
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease
Kenneth I. Ataga, Abdullah Kutlar, Julie Kanter et al. · New England Journal of Medicine · 2016 · 876 citations · Full text
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease
Elliott Vichinsky, Carolyn Hoppe, Kenneth I. Ataga et al. · New England Journal of Medicine · 2019 · 609 citations · Full text
Transgenic sickle mice have vascular inflammation
John D. Belcher, Chris Bryant, Julia Nguyen et al. · Blood · 2003 · 235 citations · Full text
Donna Oksenberg, Kobina Dufu, Mira Patel et al. · British Journal of Haematology · 2016 · 235 citations · Full text